Holen Sie sich die Stockscreener-App
34.02
2.26%
-0.965
Schlusskurs vom Vortag:
$34.98
Offen:
$34.52
24-Stunden-Volumen:
65,084
Relative Volume:
0.10
Marktkapitalisierung:
$1.09B
Einnahmen:
$4.85M
Nettoeinkommen (Verlust:
$-114.75M
KGV:
-10.47
EPS:
-3.25
Netto-Cashflow:
$-100.36M
1W Leistung:
+2.00%
1M Leistung:
-2.15%
6M Leistung:
+57.56%
1J Leistung:
+22.06%
1-Tages-Spanne:
$33.85
$35.40
1-Wochen-Bereich:
$32.89
$35.40
52-Wochen-Spanne:
$13.37
$40.16
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Vergleichen Sie DNTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
33.90 | 1.39B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.50 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.12 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
828.79 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.35 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Trend analysis for Dianthus Therapeutics Inc. this weekJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
Why Dianthus Therapeutics Inc. stock remains resilientDay Trade & Weekly Market Pulse Updates - newser.com
Will Dianthus Therapeutics Inc. (87E) stock hit Wall Street targetsJuly 2025 Sentiment & Entry Point Confirmation Alerts - newser.com
How to escape a deep drawdown in Dianthus Therapeutics Inc.Gap Up & Growth Focused Stock Reports - newser.com
What recovery options are there for Dianthus Therapeutics Inc.Weekly Earnings Recap & Accurate Intraday Trading Signals - newser.com
Will Dianthus Therapeutics Inc. (87E) stock outperform value peersJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Using Python tools to backtest Dianthus Therapeutics Inc. strategiesProfit Target & AI Forecast for Swing Trade Picks - newser.com
Will Dianthus Therapeutics Inc. stock see PE expansionJuly 2025 Sector Moves & Daily Entry Point Trade Alerts - newser.com
Will Dianthus Therapeutics Inc. (87E) stock gain from green policiesMarket Risk Summary & Expert Verified Movement Alerts - newser.com
Long term hold vs stop loss in Dianthus Therapeutics Inc.2025 Momentum Check & Fast Moving Stock Watchlists - newser.com
Dianthus Therapeutics Inc. stock chart pattern explainedMarket Risk Report & Community Trade Idea Sharing Platform - newser.com
Using Bollinger Bands to evaluate Dianthus Therapeutics Inc.July 2025 Review & AI Optimized Trade Strategies - newser.com
Is Dianthus Therapeutics Inc. (87E) stock a fit for income portfoliosGold Moves & High Accuracy Investment Signals - newser.com
Smart tools for monitoring Dianthus Therapeutics Inc.’s price actionWeekly Investment Summary & Low Risk Entry Point Guides - newser.com
Can Dianthus Therapeutics Inc. stock hit analyst price targetsWeekly Gains Report & Verified Momentum Stock Alerts - newser.com
Dianthus Therapeutics, Inc. (DNTH) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Using economic indicators to assess Dianthus Therapeutics Inc. potentialWeekly Gains Summary & Risk Managed Trade Strategies - newser.com
Dianthus Therapeutics (DNTH) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
What to expect from Dianthus Therapeutics Inc. in the next 30 daysJuly 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
How to monitor Dianthus Therapeutics Inc. with trend dashboardsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Dianthus Therapeutics, Inc. (DNTH) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
How New Phase 2 MaGic Data on Claseprubart Has Changed the Investment Story at Dianthus Therapeutics (DNTH) - Sahm
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting - The Manila Times
Dianthus Therapeutics Reports Positive Phase 2 MaGic Trial Data for Claseprubart in Generalized Myasthenia Gravis and Plans Phase 3 Trial Initiation in 2026 - Quiver Quantitative
Dianthus (NASDAQ: DNTH) plans Phase 3 gMG with two claseprubart arms and QMG≥10 criterion - Stock Titan
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - MSN
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):